02 - Laserfiche WebLink

S2 Genomics Paves the Way for Future Single Cell Genomics Research - A Brief With Stevan Jovanovich, Founder & CEO S2 Genomics has developed a tissue sample preparation system to process solid tissues into single cells and nuclei for Next Generation Sequencing. S2 simplifies the complexities of preparing single cell and single nuclei suspensions. The system uses tissue-specific protocols and reagent sets for generating single cells and a universal protocol and reagent set for generating single nuclei. This effectively lays the foundation for standardized research around single cell genomics. S2 currently has early prototype systems and is installing them at some of the top genomics research centers across the world. Stevan Jovanovich, Ph.D. founded this company in 2o16. His previous company, IntegenX, was acquired by Thermo Fisher (NYSE: TMO) in 2018. "Single cell genomics is the equivalent of getting down to the atomic level. It's growing very rapidly now but is hampered by sample preparation issues, We have a system, it works, it's sequence verified, and so it's an exciting time for S2 Genomics." Being in the Tri -Valley - "We actually started IntegenX in Fremont but moved to Dublin after a year since several of us live in the Tri -Valley. So naturally, that's where we started S2. At one point [IntegenX) had over 175 employees. With the two National Labs right here, and being in good commuting distance from the Central Valley and Bay Area, it was pretty easy to hire the right people, many of whom live the Tri -Valley and were thrilled to eliminate the long commute down to Silicon Valley." 25 "With the two National Labs right here, and being in good commuting distance from the Central Valley and Bay Area, it Was pretty easy to hire the right people" Stevan Jovanovich, Founder & CEO